Get the Stockscreener App
3.19
8.14%
0.24
After Hours:
3.40
0.21
+6.58%
Cyclerion Therapeutics Inc stock is traded at $3.19, with a volume of 267.49K.
It is up +8.14% in the last 24 hours and up +52.63% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$2.95
Open:
$3.03
24h Volume:
267.49K
Relative Volume:
0.09
Market Cap:
$8.65M
Revenue:
$556.00K
Net Income/Loss:
$-5.28M
P/E Ratio:
-0.1833
EPS:
-17.4
Net Cash Flow:
$-6.23M
1W Performance:
-7.00%
1M Performance:
+52.63%
6M Performance:
+39.91%
1Y Performance:
-24.94%
1-Day Range:
$2.8345
$3.43
1-Week Range:
$2.80
$3.79
52-Week Range:
$1.27
$9.4699
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
3.19 | 8.65M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
Cyclerion Therapeutics (NASDAQ: CYCN) Amends License Agreement with Akebia Therapeutics and Generates Revenues for GrowthOn December 17, 2024, Cyclerion Therapeutics, Inc. filed an 8-K SEC Filing which detailed significant developments in its b - Defense World
Cyclerion advances growth strategy with new agreements - Investing.com
Cyclerion Therapeutics Secures Funding and Expands CNS Focus - TipRanks
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewswire
Cyclerion Strikes $560M Milestone Deal with Akebia, Completes Portfolio Monetization Strategy - StockTitan
Head to Head Survey: Cyclerion Therapeutics (NASDAQ:CYCN) vs. scPharmaceuticals (NASDAQ:SCPH) - Defense World
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update - Defense World
3 US Penny Stocks With Market Caps Under $100M - Simply Wall St
Cyclerion stock hits 52-week high at $5.25 amid market fluctuations - Investing.com Canada
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com
Stock market news: Cyclerion Therapeutics +280.50%, Cross Country Healthcare +62.01% among top gainers during mid day trading - Business Upturn
Stock market news: Relmada Therapeutics plunged by 75.54% while Cyclerion Therapeutics surged by 280.12% during mid day trading - Business Upturn
Stock market today: Cyclerion Therapeutics +343.79%, Cross Country Healthcare +63.04% among top gainers in early trading - Business Upturn
Stock market today: Relmada Therapeutics declined by 74.74% while Cyclerion Therapeutics saw surge of 392.22% in early trading - Business Upturn
Cyclerion stock hits 52-week high at $5.25 amid market fluctuations By Investing.com - Investing.com South Africa
CYCN (Cyclerion Therapeutics) 3-Year EBITDA Growth Rate : 57.30% (As of Sep. 2024) - GuruFocus.com
CYCN (Cyclerion Therapeutics) GF Value Rank : 5 (As of Nov. 25, 2024) - GuruFocus.com
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cyclerion stock hits 52-week low at $1.55 amid market challenges - Investing.com Canada
Cyclerion stock hits 52-week low at $1.55 amid market challenges By Investing.com - Investing.com South Africa
Cyclerion Therapeutics Inc (CYCN) Quarterly 10-Q Report - Quartzy
Cyclerion Therapeutics stock hits 52-week low at $1.75 By Investing.com - Investing.com South Africa
Cyclerion Therapeutics stock hits 52-week low at $1.75 - Investing.com India
Where Are They Now? Ironwood Pharmaceuticals - Life Science Leader Magazine
Vascular Dementia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP - Barchart
cyclerion therapeutics, inc. Earnings dates - RTTNews
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 8.1% - Defense World
Analyzing Cyclerion Therapeutics (NASDAQ:CYCN) and Seelos Therapeutics (NASDAQ:SEEL) - Defense World
Cyclerion appoints Regina Graul as CEO and President - Investing.com
Cyclerion Therapeutics Promotes Regina Graul, Ph.D., to Chief Executive Officer - citybiz
Regina Graul, Ph.D., Promoted to Chief Executive Officer - StreetInsider.com
Short Interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Expands By 10.9% - Defense World
Cyclerion Therapeutics - BioSpace
Head-To-Head Analysis: Genelux (NASDAQ:GNLX) and Cyclerion Therapeutics (NASDAQ:CYCN) - Defense World
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday - Quantisnow
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer - Marketscreener.com
Cyclerion Appoints Regina Graul, Ph.D., as President - GlobeNewswire
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewswire
Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses - Yahoo Finance
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment - Marketscreener.com
Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member - Business Wire
Tisento Therapeutics Raises $81M in Series A Funding - FinSMEs
Bio Startup Tisento Launches With $81M and a Brain-Penetrating Drug in the Clinic - MedCity News
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Cyclerion Announces Reverse Stock Split - Yahoo Finance
Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors - Yahoo Finance
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 - GlobeNewswire
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement - GlobeNewswire
Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer - Business Wire
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results - Yahoo Finance
BioMarin, Cyclerion Slash Workforce in the Name of Strategic Focus - BioSpace
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):